PER 4.29% 6.7¢ percheron therapeutics limited

Where others have failed will Atl1102 succeed ?, page-800

  1. 4,336 Posts.
    lightbulb Created with Sketch. 2023
    I think if they do go with Capricor it would also be a very good thing for ANP.

    Two drugs with questional abilities to treat DMD combined, could help open a larger market share for ANP. This is if previous results can be replicated for the ANP drug.

    So much to look forward to. A maccas outing. Taking itsas Lambo for a blat. Watching Davo and Rochem see if their Rovers can really climb walls. All while mephistophles stops the boys from fighting over the maccas apple pie.

    Bring it on.
 
watchlist Created with Sketch. Add PER (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.